Scarica l'app Stockscreener
0.3606
10.52%
-0.0424
Pre-mercato:
.36
-0.0006
-0.17%
Precedente Chiudi:
$0.403
Aprire:
$0.399
Volume 24 ore:
156.02K
Relative Volume:
1.20
Capitalizzazione di mercato:
$13.08M
Reddito:
-
Utile/perdita netta:
$-8.64M
Rapporto P/E:
-1.408
EPS:
-0.2561
Flusso di cassa netto:
$-5.41M
1 W Prestazione:
-2.09%
1M Prestazione:
-2.20%
6M Prestazione:
-73.49%
1 anno Prestazione:
-42.03%
Intervallo 1D:
$0.3605
$0.4003
Intervallo di 1 settimana:
$0.35
$0.4189
Portata 52W:
$0.3062
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Nome
Jupiter Neurosciences Inc
Settore
Industria
Telefono
(561) 406-6154
Indirizzo
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.3606 | 13.08M | 0 | -8.64M | -5.41M | -0.2561 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jupiter Neurosciences Inc Borsa (JUNS) Ultime notizie
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit - TradingView
[EFFECT] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan
JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jupiter: Rise in AUMs Driven by CCLA Acquisition Completion, Net Inflows - Moomoo
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 - WFXG
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Jupiter Neurosciences (NASDAQ: JUNS) files shelf to sell up to $100M in securities - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 - The Globe and Mail
Nasdaq hosts Jupiter Neurosciences CEO at April 14 investor conference - Stock Titan
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - The Joplin Globe
Growth Review: Will Jupiter Neurosciences Inc benefit from rising consumer demand2026 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Winners Losers: What are analysts price targets for EMP PRAEarnings Risk Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - Caledonian Record
JUNS PE Ratio & Valuation, Is JUNS Overvalued - Intellectia AI
Forecast Cut: What analysts say about Jupiter Neurosciences Inc stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Swing Trade: Can Avis Budget Group Inc sustain earnings growth2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board - The National Law Review
Investment Review: Will Jupiter Neurosciences Inc benefit from rising consumer demandMarket Movers & Safe Entry Point Identification - baoquankhu1.vn
Jupiter Neurosciences adds advisors for consumer product line By Investing.com - Investing.com Australia
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board - Bitget
Jupiter Neurosciences adds advisors for consumer product expansion By Investing.com - Investing.com Canada
Jupiter Neurosciences adds advisors for consumer product expansion - Investing.com
Jupiter Neurosciences adds advisors for consumer product line - Investing.com
Breakout Move: Is Jupiter Neurosciences Inc forming a bullish divergence2026 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
JUNS SEC FilingsJUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan
How does earnings affect Jupiter Neurosciences (JUNS) Stock | Price at $0.40, Up 4.18%Stock Market Community - Newser
JUNS Stock Analysis: Jupiter Neurosciences Inc. Biotech 2.9% Dip Update at $0.37 - UBND thành phố Hải Phòng
Jupiter Neurosciences, Inc. Advances JOTROL™ Resveratrol Platform for Neuroinflammation Treatments and Launches Nugevia Longevity Supplements 69 70 73 108 - Minichart
Jupiter Neurosciences Delays Annual 10-K Filing - TipRanks
Jupiter Neurosciences 2025 10-K: $21.8K Revenue, $0.00 EPS (net loss $8.64M) - TradingView — Track All Markets
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Jupiter Neurosciences (JUNS) flags going concern risk and expands JOTROL, Nugevia strategy - stocktitan.net
[NT 10-K] JUPITER NEUROSCIENCES, INC. SEC Filing - stocktitan.net
Breakout Move: Will Jupiter Neurosciences Inc benefit from geopolitical trends2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
North Country Limousine Opens 2026 Wine Tour Reservations for Long Island’s North Fork - weeklyvoice.com
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 - The Norfolk Daily News
Investors can hear Jupiter Neurosciences outline progress Apr. 2 - Stock Titan
Will The GEO Group Inc outperform during market ralliesPortfolio Value Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Nasdaq Moves: Does Jupiter Neurosciences Inc outperform in volatile marketsQuarterly Investment Review & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Growth Recap: How is Mersana Therapeutics Inc managing supply chain issues2026 Market Outlook & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Market Moves: What analysts say about Jupiter Neurosciences Inc stockWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Centri - TMX Newsfile
Jupiter Neurosciences Inc Azioni (JUNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):